PMC:7319919 / 4383-4716 9 Projects
Annnotations
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T37 | 0-333 | Sentence | denotes | Although developed targeting the oncogenic fusion protein BCR-ABL, imatinib is able to inhibit other tyrosine kinases such as c-KIT, platelet-derived growth factor receptor and Abelson kinases (ABL) type 1 and 2 [4]; therefore, it has been postulated that the biological activity of this drug is not restricted to anticancer effects. |